Learn about the researchers in the lab and out in the field who are undertaking innovative research and making unique discoveries for the University of Sydney’s Lambert Initiative.
Dr Anand Gururajan obtained his degree in Pharmacy at the University of South Australia in 2006 followed by a PhD in Neuropharmacology at Monash University in 2008. His doctoral research project was focussed on investigating the antipsychotic potential of cannabidiol in preclinical models of aspects of schizophrenia. From 2011 to 2013, he gained further experience as a postdoctoral researcher at the Florey Institute of Neuroscience and Mental Health where he disentangled the complex interactions between genetic and environmental risk factors associated with schizophrenia and depression.
In 2015, Anand moved to University College Cork (Ireland) where he carried out a clinical research project to identify diagnostic biomarkers of depression. In the following year he was awarded the Marie-Curie Individual Actions Research fellowship by the European Research Commission to investigate the central and peripheral basis of resilience to chronic stress. In 2018, Anand was awarded the University of Sydney Research Fellowship to investigate the molecular mechanisms of action for various phytocannabinoids with potential for the treatment of post-traumatic stress disorder. He is also an ad-hoc lecturer in the Department of Pharmacology.
Dr Lyndsey Anderson is a preclinical researcher from Wisconsin, United States. She completed a Bachelor of Science in Pharmacology and Toxicology with a double major in Biology from the University of Wisconsin, followed by a PhD at Vanderbilt University, where she focused on the pharmacology of sodium channel mutations associated with human epilepsy and examined novel anticonvulsants in genetic mouse models of epilepsy.
Following her PhD, she undertook a postdoctoral fellowship at Northwestern University Feinberg School of Medicine.At Northwestern, Lyndsey pursued research on pharmacogenomics of drug-drug interactions and continued her in-vivo pharmacology work in an epilepsy model.
She joined the Lambert Initiative in May 2016, where she continues preclinical therapy screening of cannabinoids for the treatment of Dravet syndrome, a rare and severe form of paediatric epilepsy.
Anastasia Suraev graduated with a Bachelor of Advanced Science (Honours in Psychology) at the University of Sydney. Following this, she completed a Masters in Psychology (Clinical Neuropsychology) at the University of Melbourne in 2015, where her thesis focused on the cognitive outcomes of people with a severe and treatment-resistant epilepsy known as Lennox-Gastaut Syndrome.
In early 2016, she began working as a Clinical Research Officer at the Lambert Initiative where she coordinated the PELICAN research study. Currently, her main role involves providing expertise into decisions regarding study design and cannabinoid-based drugs on a range of clinical research projects. She also actively engages in community outreach through news media and invited talks on the topic of cannabinoid medicine. Anastasia is also partway through her PhD where she is coordinating a clinical trial examining the effects of a cannabinoid-based therapy on sleep and daytime function in people with chronic insomnia, which she is conducting in partnership with Sleep & Circadian Research Group at the Woolcock Institute of Medical Research.
Dr Adam Ametovski graduated with a Bachelor of Science (Hons I) in 2014 followed by a PhD in Synthetic Organic Chemistry, both from Monash University. His research to date has focused on the development of new catalytic chemical reactions to enable the preparation of complex bioactive molecules in an efficient manner. In this regard his most recent work details the synthesis of THC.
Adam joined the Lambert Initiative in September 2019 where his work will involve the creation of small chemical libraries of novel cannabinoid compounds (ie. synthetic cannabinoids). This will include the preparation of CBD, CBG and CBC, amongst others, in the pursuit of new drugs for the treatment of epilepsy and related conditions.
Dr Elizabeth Cairns is a postdoctoral researcher from Nova Scotia, Canada and one of the world’s leading experts in the use of cannabinoids for the treatment of glaucoma. She completed a Bachelor of Science in Biology from the University of Prince Edward Island, then in 2017 she completed her PhD in Pharmacology and Neuroscience at Dalhousie University in Halifax under the supervision of Dr Melanie Kelly. From 2018-2019, Dr Cairns completed postdoctoral work involving screening novel compounds for two blinding eye diseases that affect infants under the supervision of Drs Christopher McMaster and Johane Robitaille. Dr Cairns is also passionate about scientific communication and has written extensively about the basics of the endocannabinoid system and associated research.
She joined the Lambert Initiative in May 2019 and is currently exploring projects that build on her prior experience in cannabinoids and neurodegenerative conditions such as Alzheimer’s disease and traumatic brain injury.
After earning a Bachelor of Science from Monash University in 2011, Dr Danielle McCartney worked as a clinical research assistant at the Baker IDI Heart and Diabetes institute in their Hypertension & Kidney Disease Laboratory in Melbourne. In 2015, she returned to her studies, completing a master’s degree in Nutrition & Dietetics (Research) which she completed in 2016, followed by her PhD in 2019, both from Griffith University. During her master’s degree, she studied the impact of acute alcohol intoxication on cognitive function and simulated car driving performance; whereas her doctoral research focused on nutritional strategies to enhance post-exercise recovery and subsequent athletic performance. Danielle joined the Lambert Initiative in March 2019 where her main role is to coordinate clinical research into the effects of cannabidiol on simulated car driving performance.
Dr Richard Kevin's research has focused on the psychopharmacological evaluation of novel cannabinoid compounds (eg synthetic cannabinoids) using both analytical chemistry and rodent models. His research has established basic dose-response relationships of new cannabinoids, identified potential long-term effects of chronic cannabinoid use, and characterised the metabolic processes for several synthetic cannabinoids.
Richard will join the PELICAN research study and exercise studies; analysing patient samples for cannabinoid content and analysing tinctures for terpenoid content. Additionally, he plans to conduct studies that will identify potentially therapeutic phytocannabinoid metabolites.
Vaishali graduated with a Master in Science (Biotechnology) from Goa University in India followed by her PhD in Neuroscience at Vanderbilt University in the US where she examined the mechanism of catastrophic pediatric epilepsies resulting from dysfunctional GABAA receptors.
Whilst at Vanderbilt, she received the Clinical Neuroscience Scholars’ Fellowship, which brought her into contact with children (and the families of children) who suffer from catastrophic epilepsies. She then worked in drug discovery in San Francisco, looking specifically at epilepsies and in particular, Dravet Syndrome
Vaishali joined the Lambert Initiative in August 2019 as a postdoctoral research associate where she is contributing to preclinical epilepsy research. Her work will aid in identifying the effectiveness of cannabinoid compounds in alleviating seizures and understanding their mechanisms of action on known and untargeted brain molecules.
Michael Udoh completed his Bachelor of Pharmacy degree at the University of Uyo, Nigeria in 2011. After his pharmacist registration, he proceeded to complete a Masters degree in Drug Discovery and Pharmaceutical Sciences at the University of Nottingham, UK; where he was involved in the design and development of CCR5 receptor analogues for the treatment of HIV infections. Michael recently completed his PhD in Molecular Pharmacology/Biomedical Sciences at Macquarie University. His research under the guidance of Prof Mark Connor focused on investigating the molecular pharmacology of less known phytocannabinoids -such as cannabichromene (CBC)- at selected G protein-coupled receptors and ion channels.
Michael joined the Lambert Initiative in February 2020 where his work will include the characterisation of phytocannabinoids and novel chemical entities at selected drug targets for the treatment of Dravet syndrome. Additionally, he plans to conduct studies to develop novel phytocannabinoid-based therapies for the treatment of chronic pain.
Zeeta graduated from the University of Sydney with a degree in Pharmacy. Post qualification, she attained the position of head pharmacist at two large community pharmacies. She served as the New South Wales Intern Training Program Coordinator at the Pharmaceutical Society of Australia, the peak professional body for pharmacists. She has also worked at Bayer as a Medical Information Associate and Sanofi as a Medical Affairs Associate.
Zeeta’s first foray into research was as a Clinical Pharmacist and a Research Assistant in Chronic Obstructive Pulmonary Disease studies at the Woolcock Institute of Medical Research.
Zeeta joined the Lambert Initiative in May 2020 as a clinical trial coordinator to assist with the HUSH Trial which explores the use of low dose CBD in treating insomnia patients presenting themselves to community pharmacies.